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Abstract
Background: During infection, there is an activation of the L-arginine-nitric-oxide pathway, with a shift from nitric
oxide synthesis to a degradation of L-arginine to its metabolites, asymmetric and symmetric dimethylarginine
(ADMA and SDMA). However, the prognostic implications for short-term or long-term survival remains unclear.
We investigated the association of L-arginine, ADMA, and SDMA with adverse clinical outcomes in a well-defined
cohort of patients with community-acquired pneumonia (CAP).
Methods: We measured L-arginine, ADMA, and SDMA in 268 CAP patients from a Swiss multicenter trial by mass
spectrometry and used Cox regression models to investigate associations between blood marker levels and disease
severity as well as mortality over a period of 6 years.
Results: Six-year mortality was 44.8%. Admission levels of ADMA and SDMA (μmol/L) were correlated with CAP severity
as assessed by the pneumonia severity index (r = 0.32, p < 0.001 and r = 0.56, p < 0.001 for ADMA and SDMA, respectively)
and higher in 6-year non-survivors versus survivors (median 0.62 vs. 0.48; p < 0.001 and 1.01 vs. 0.85; p < 0.001 for ADMA
and SDMA, respectively). Both ADMA and SDMA were significantly associated with long-term mortality (hazard ratios [HR]
4.44 [95% confidence intervals (CI) 1.84 to 10.74] and 2.81 [95% CI 1.45 to 5.48], respectively). The effects were no longer
significant after multivariate adjustment for age and comorbidities. No association of L-arginine with severity and
outcome was found.
Conclusions: Both ADMA and SDMA show a severity-dependent increase in patients with CAP and are strongly
associated with mortality. This association is mainly explained by age and comorbidities.
Trial registration: ISRCTN95122877. Registered 31 July 2006.
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Background
Nitric oxide (NO), which is synthesized from L-arginine
by nitric oxide synthases (NOS), is a vaso- and bron-
chodilator [1]. Its deficiency results in airway hyperre-
activity [2] and endothelial dysfunction [3]. In addition,
nitric oxide inhibits platelet adhesion and is considered
to have a role in nonspecific immunity [4]. Arginase,
which converts L-arginine into L-ornithine and urea,
reduces the bioavailability of L-Arginine for NOS and
thereby inhibits the L-Arginine-Nitric oxide pathway
[5]. L-arginine residues are methylated by protein
methyltransferases (PRMT). Asymmetric and symmet-
ric dimethylarginine (ADMA and SDMA) are derived
from the proteolysis of these methylated arginines on
various proteins (Fig. 1) [6, 7]. While ADMA acts as a
competitive inhibitor of the NOS, SDMA is a competi-
tor of arginine transport but does not interfere with
NOS [8]. Thus, an elevated serum ADMA level results
in lowered NO levels, which leads to vasoconstriction,
augmented thrombocyte aggregation, and cell adhesion
to the endothelium and promotes proliferation of
vascular muscle cells [9]. ADMA is metabolized to citrul-
line and dimethylamine by the enzyme dimethylarginine
dimethylaminohydrolase (DDAH) and a small fraction is
renally excreted whereas SDMA is almost entirely elimi-
nated by the kidneys. There is also a negative feedback
loop of NO, with high NO concentrations leading to the
inhibition of DDAH [10].
Circulating levels of ADMA are elevated in multiple
diseases with endothelial dysfunction (e.g., hypertension,
hyperlipidemia, diabetes mellitus, atherosclerosis, and
renal failure) [3, 6, 11–14], in diseases of the respiratory
system (e.g., asthma and COPD) [2, 15], and in multiple
organ failure in sepsis [16]. Its isomer, SDMA, is also as-
sociated with a higher prevalence of cardiovascular risk
factors as well as all-cause and cardiovascular mortality
[10, 17]. Increased plasma concentrations of ADMA and
SDMA are independent prognostic factors for short-term
and long-term mortality in critically ill patients [18, 19]. In
contrast, high levels of serum SDMA, but not of ADMA,
seem to be an independent prognostic biomarker of
all-cause mortality in the general population [17].
Fig. 1 Metabolism of nitric oxide. Nitric oxide (NO) is synthesized from L-arginine. This reaction is catalyzed by nitric oxide synthases (NOS). Protein
synthesis incorporates L-arginine into proteins. Protein-bound L-arginine is methylated by protein methyltransferases (PRMT) and lysed to the
metabolites asymmetric and symmetric dimethylarginine (ADMA, SDMA). ADMA is mainly metabolized to citrulline and dimethylamine via dimethylarginine
dimethylaminohydrolase (DDAH). A small fraction of ADMA and almost the entire amount of SDMA are renally eliminated. ADMA inhibits the
NOS competitively and SDMA interferes with L-arginine transport. Arginase reduces the bioavailability of L-arginine by degrading it to L-ornithine and
urea. Nitric oxide has a negative feedback mechanism to DDAH, which leads to less metabolism of ADMA
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Both, ADMA and SDMA are increased in elder people
[20]. In addition, a lowered ratio of arginine to ADMA
is a sensitive risk marker for atherosclerosis, cardiovas-
cular disease, and mortality in patients with shock,
being even more sensitive than ADMA alone [21, 22].
Community-acquired pneumonia (CAP) is to date one
of the leading causes of death due to an infection [23].
CAP is also associated with an increased risk of cardio-
vascular events and, thus, is an independent cardiovas-
cular risk factor [24–26]. The aim of our study was to
evaluate the role of L-arginine, ADMA, and SDMA in
the pathophysiology of CAP. We also wanted to deter-
mine whether the ratio of arginine to ADMA correlates
with disease severity and mortality in CAP patients over
a follow-up period of 6 years.
Methods
Study design
A total of 268 patients with a definite diagnosis of CAP
and available blood samples from a previous Swiss mul-
ticenter trial (the ProHOSP trial) [27, 28] were included
in this investigation. The initial trial included 925 (68%)
CAP patients with an all-cause mortality of 45% who
were followed up over a period of 6 years [29].
The initial trial was a noninferiority randomized con-
trolled trial evaluating the economical use of antibiotics
at six Swiss secondary and tertiary care centers between
October 2006 and March 2008 [27]. The primary goal of
the study was to verify the efficacy and safety of using
serum procalcitonin (PCT) levels to guide the initiation
and duration of antibiotic therapy in patients with lower
respiratory tract infections [27, 28]. Patients ≥18 years of
age presenting from the community or a nursing home
to the emergency department (ED), were included if they
met at least one of the following criteria: cough, dys-
pnea, pleural pain, sputum production, or tachypnea and
one sign of an infection (core body temperature >38 °C,
shivering, white blood cell count >10 or <4x109 cells/L),
or one clinical finding upon auscultation (rales or crepi-
tation). An infiltrate was radiologically confirmed in all
patients with CAP. Exclusion criteria included language
restriction or dementia that precluded patients from giving
written informed consent, intravenous drug use, a terminal
condition, or hospital-acquired pneumonia (HAP). Partici-
pants were accepted into the study if they had received
short-term antibiotic pretreatment or corticosteroids, but
were excluded if they had obtained long-term antibiotic
pretreatment or suffered from severe immunosuppression
at ED presentation.
Analysis of blood biomarkers
Blood samples collected from each patient and frozen in
aliquots at ED admission were used for measuring the
different biomarkers. Baseline arginine, ADMA, and
SDMA levels were measured in blood samples of all 268
CAP patients included in the study, with 109 of them
also having blood specimens available at day 7 of
hospitalization for these measurements. If any of above
biomarkers had a value of 0, it was considered to be a
measuring error and excluded from the analysis. Due to
technical errors or insufficient volume of blood speci-
mens during biomarker measurement, not all patients
had a complete set of markers. The final analysis in-
cluded 268 patients of which 268 (100%) had complete
markers of arginine, while 233 (87%) and 242 (90%) had
ADMA and SDMA markers available, respectively.
Liquid chromatography tandem-mass spectrom-
etry (LC-MS/MS) analysis was performed using an Ul-
timate 3000 UHPLC (Thermo Fisher, San Jose, USA)
system coupled to an ABSciex 5500 quadrupole mass
spectrometer (ABSciex, Darmstadt, Germany) and the
AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG,
Innsbruck, Austria) [30–32]. Sample preparation and
measurements were performed as described in the Abso-
luteIDQ p180 user’s manual. Chromatographic separ-
ation was performed on a Thermo Syncronis aQ
50x2.1 mm 1.7 μm column. The prepared samples were
analyzed using multiple reaction monitoring (MRM).
Selected metabolites were quantified by reference to
appropriate internal standards. All concentrations were
reported in μM.
Main outcome measurements
The primary endpoint was all-cause mortality after a
follow-up period of 6 years. Secondary endpoints were
mortality at day 30 and 1-year, ICU admissions, and
clinical findings (pneumonia severity index [PSI] and
quick Sepsis Related Organ Failure Assessment [qSOFA]
score) [33]. Vital status was ascertained through struc-
tured phone interviews by trained medical students at
days 30, 180, and 540, and at 6 years [29, 34]. If patients
or their household members could not be reached, the
treating general practitioners were contacted.
Statistical analyses
All statistical analyses were performed using STATA
12.1 (Stata Corp, College Station, TX, USA). Statistical
significance was considered at a p value <0.05. Categorical
variables are expressed as percentages (numbers) and con-
tinuous variables as medians (interquartile range [IQR])
unless stated otherwise. The distribution of ADMA,
SDMA, and L-arginine (just referred to as biomarkers
henceforth) were skewed. The distribution of the bio-
markers approximated a normal distribution after loga-
rithmic transformation at a base of 10. Chi-square (Wald)
tests were used for frequency comparisons, and nonpara-
metric tests (Mann-Whitney U, Kruskal-Wallis, and Spear-
man’s rank correlation) were executed for comparisons of
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two or more groups. The significance levels were subjected
to Bonferroni adjustment. To study the association of co-
morbidities with initial biomarker levels, we used univariate
and multivariate linear regression models. To investigate
associations between biomarker levels at baseline and all-
cause mortality, we utilized univariate and multivariate Cox
regression models. These associations are reported as haz-
ard ratios (HRs) with 95% confidence intervals (CIs) and
significance levels for the chi-square (Wald) test. Odds ra-
tios were calculated and reported with 95% confidence
intervals (CIs). Area under the receiver operating char-
acteristics curves (AUCs) with 95% CIs are presented to
illustrate discrimination and predictive power. Mortal-
ity based on biomarker quartiles (highest versus lower
three) has been illustrated through the use of Kaplan-
Meier curves. All analyses were performed with the ra-
tio of arginine to ADMA as well.
Results
Patient characteristics
Baseline characteristics of the entire cohort (N = 268)
as well as for patients stratified by 6-year survival
status are presented in Table 1. The median age of the
entire cohort was 72 years and 40.7% were female.
There was a high burden of comorbidities, with 18.3%
having a history of coronary artery disease (CAD),
23.9% having chonic renal failure (CRF), and 26.1%
having chronic obstructive pulmonary disease (COPD).
Association between the investigated biomarkers
(L-arginine, ADMA, SDMA) and mortality
Mortality at day 30 was 5.2% (n = 14), increasing to 17.9%
(n = 48) after 1 year and 44.8% (n = 120) after 6 years of
follow up. Figure 2 shows Kaplan-Meier curves for 6-year
all-cause mortality based on the highest quartile compared
to lower quartiles of arginine, ADMA and SDMA.
Baseline levels of ADMA and SDMA were increased in
6-year non-survivors compared with survivors (ADMA me-
dian, 0.62 μmol/L [IQR 0.47–0.83] vs. 0.48 μmol/L [IQR
0.38–0.67]; p <0.001 and SDMA median, 1.01 μmol/L [IQR
0.63–1.38] vs. 0.85 μmol/L [IQR 0.52–1.00]; p <0.001).
There were no significant differences in arginine levels be-
tween non-survivors and survivors (median, 41.3 μmol/L
[IQR 29.6–62.2] vs. 43.3 μmol/L [IQR 28.2–64.3]; p = 0.97)
(see Table 1).
In Cox regression analyses, while ADMA, SDMA, and
their ratios were found to be associated with long-term
mortality, only SDMA was related to short-term mortality.
This association did not remain robust following adjust-
ment for different comorbidities. Further analyses revealed
an AUC of SDMA of 0.71 (95% CI 0.56 to 0.87) for short-
and mid-term mortality and 0.64 (95% CI 0.57 to 0.71) for
long-term mortality at 6 years. The AUCs for ADMA did
not reach these levels (Table 2).
Association between biomarkers and severity
In Spearman’s rank correlation analyses with Bonferroni
adjustment, we found significant associations of ADMA
and SDMA with the Pneumonia Severity Index (ρ = 0.31,
p <0.001 and ρ = 0.5307, p <0.001). In contrast, there
was no association between all the investigated bio-
markers and the qSOFA score.
Association of biomarkers with comorbidities
We developed linear regression models investigating
predictors for increased biomarker levels. Univariate
analysis showed significant correlation of SDMA and
ADMA to numerous comorbidities and patient charac-
teristics (Table 3). The multivariate models revealed that
higher levels of SDMA are seen in patients with chronic
renal failure, COPD, and in older patients. Levels of
SDMA therefore showed a better correlation to comor-
bidities than ADMA, which was associated only with age
and neoplastic disease. Levels of arginine did not show
any correlation whatsoever (Table 4).
Discussion
The findings of this first study to investigate arginine,
ADMA, and SDMA levels in CAP patients revealed that
high levels of ADMA and SDMA measured upon ED
admission are strongly associated with mid- and long-
term mortality, and that high levels of SDMA are associ-
ated with short-term mortality. However, this effect wore
off after adjustment for comorbidities and age. That
leads us to the assumption that this association is mainly
defined by the correlation of the biomarkers to several
comorbidities like chronic renal failure or COPD and
age. Supporting this assumption is the finding that
SDMA is also well correlated with PSI but not with the
qSOFA score. In contrast, the other biomarkers were
not correlated with any of these scores. Arginine did not
show any association with mortality or any secondary
outcome.
High levels of SDMA and ADMA are indeed associ-
ated with mortality [10, 17–19], but we found that this
correlation is mainly defined by comorbidities and age.
Several studies have found ADMA and SDMA to be as-
sociated with chronic renal failure, COPD, asthma, sep-
sis, cardiovascular risk factors, and cardiovascular and
all-cause mortality [2, 3, 6, 10–17]. In short, these two
biomarkers are associated with diseases characterized by
vascular and bronchial dysfunction. This association
could be causal or caused by an imbalance of nitric
oxide production [2, 3]. That does not diminish the
prognostic value of these markers, but instead shows
that they rather provide an overview of the general
health status of a patient. This strong correlation with
comorbidities, particularly with renal failure, partly ex-
plains the good association with the pneumonia risk
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scores. Our study transfers these findings to patients
with CAP, where an association of ADMA, SDMA, and
all-cause mortality was found. In contrast to O’Dwyer et
al. we did not find a correlation of these biomarkers with
sepsis severity [16]. One reason may be, that we assessed
sepsis severity by the qSOFA score and O’Dwyer by the
SOFA score, which has more power. The other reason
may be the limitation, that we did not assess the qSOFA
Table 1 Baseline characteristics: overall and by 6-year vital status
Factor Total Survivor Non-Survivor p value
N 268 148 120
Demographic characteristics
Age, median (IQR) 72 (57, 82) 63 (43, 75) 80 (71, 86) <0.001
Gender, n (%) Male 159 (59.3%) 78 (52.7%) 81 (67.5%) 0.014
Female 109 (40.7%) 70 (47.3%) 39 (32.5%)
Smoking status
Current Smoker, n (%) Non-smoker 193 (72.0%) 96 (64.9%) 97 (80.8%) 0.004
Smoker 75 (28.0%) 52 (35.1%) 23 (19.2%)
Ever-Smoker, n (%) Never-smoker 169 (63.1%) 86 (58.1%) 83 (69.2%) 0.062
Ever-smoker 99 (36.9%) 62 (41.9%) 37 (30.8%)
Comorbiditesa
Coronary artery disease 49 (18.3%) 12 (8.1%) 37 (30.8%) <0.001
Congestive heart failure 33 (12.3%) 6 (4.1%) 27 (22.5%) <0.001
Cerebrovascular disease 26 (9.7%) 7 (4.7%) 19 (15.8%) 0.002
Peripheral arterial occlusive disease 15 (5.6%) 4 (2.7%) 11 (9.2%) 0.022
Chronic renal failure 64 (23.9%) 19 (12.8%) 45 (37.5%) <0.001
Diabetes mellitus 41 (15.3%) 17 (11.5%) 24 (20.0%) 0.054
Tumor 32 (11.9%) 9 (6.1%) 23 (19.2%) 0.001
Chronic obstructive pulmonary disease 70 (26.1%) 32 (21.6%) 38 (31.7%) 0.063
Vital signs
Fever, n (%) 174 (65.2%) 111 (75.0%) 63 (52.9%) <0.001
Chills, n (%) 85 (36.0%) 59 (43.7%) 26 (25.7%) 0.004
Pulse, median (IQR) 94 (82, 106) 94 (83, 108) 94 (80, 104) 0.21
Temperature, median (IQR) 38.0 (37.1, 38.8) 38.2 (37.3, 39.0) 37.8 (37.0, 38.8) 0.084
Systolic BP in mmHg, median (IQR) 130 (118, 146) 132 (120, 146) 130 (110, 148) 0.12
Severity scores
PSI 1, 2 72 (26.9%) 65 (43.9%) 7 (5.9%) <0.001
3 55 (20.5%) 36 (24.3%) 19 (15.8%)
4, 5 141 (52.7%) 47 (31.7%) 94 (78.4%)
qSOFA score 0 116 (43.3%) 78 (52.7%) 38 (31.7%) <0.001
1 127 (47.4%) 67 (45.3%) 60 (50.0%)
2, 3 25 (9.4%) 3 (2.0%) 22 (18.3%)
Metabolite concentrations (μM)
Arginine 42.8 (28.6, 63.2) 43.3 (28.2, 64.3) 41.3 (29.6, 62.2) 0.97
ADMA 0.56 (0.42, 0.73) 0.48 (0.38, 0.67) 0.62 (0.47, 0.83) <0.001
SDMA 0.85 (0.56, 1.15) 0.78 (0.52, 1.00) 1.01 (0.63, 1.38) <0.001
Arginine/ADMA Ratio 76.18 (54.08, 113.50) 85.11 (62.39, 116.58) 66.52 (48.51, 106.77) 0.004
Bolded p values are statistically significant at p < 0.05
Abbreviations: ADMA asymmetric dimethylarginine, BP blood pressure, PSI pneumonia severity index, qSOFA quick sepsis related organ failure assessment (sepsis
risk score),
SDMA symmetric dimethylarginine
aComorbidities were identified based on medical records, patient report, or both
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Fig. 2 Kaplan-Meier survival estimates for arginine (a) asymmetric dimethylarginine (ADMA) (b) and symmetric dimethylarginine (SDMA) (c). Grey
represents the lower three quartiles and black the highest quartile
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in the initial trial. So we have to consider that we under-
estimate the score because of the lack of relevant infor-
mation in some patients (see below in the limitations).
Two earlier studies found that a lower ratio of arginine
to ADMA is a more sensitive risk marker for vascular dys-
function and mortality in shock patients than ADMA
alone [21, 22]. In our population, we did not find any ad-
vantage of the ratios due to the lack of correlation of ar-
ginine with mortality and other outcomes.
Hypertension results in higher levels of ADMA and
SDMA [6, 10]. It has also been seen that administration of
ADMA results in elevated blood pressure in healthy
humans [13]. This suggests that antagonising ADMA or
SDMA is a potential new target in the therapy of
hypertension or renal failure. One way to reach this goal is
L-arginine supplementation. In animal studies, long-term
L-arginine supplementation seemed to be safe [35, 36]. In
rats it showed an attenuation of angiotensin-II - mediated
vasoconstriction [37] but in mice with type 1 diabetes it
showed no prevention or reduction of renal injury [38].
Raising arginine levels in critically ill human patients
by L-arginine supplementation has shown controversial
results relating to safety and benefit [39–43]. A meta-
analysis of double-blinded, randomized controlled trials
showed a significant lowering of systolic and diastolic
blood pressure following supplementation of L-arginine
[44]. However, there is still little evidence for supple-
mentation in patients with hypertension and there are no
studies that investigate the development of complica-
tions and progression of chronic renal failure after ad-
ministration of L-arginine.
In summary, and in contrast to previous studies, our
analysis did not reveal ADMA and SDMA to be inde-
pendent risk factors for all-cause mortality in CAP pa-
tients [10, 17]. However, in agreement with earlier
investigations, our study showed that SDMA levels de-
tected herein were strongly and independently associ-
ated with renal failure, closely related to the
glomerular filtration rate [6], and associated with
COPD [2, 15], and that ADMA and SDMA are associ-
ated with age. The independent association with age
may be due partly to the association of ADMA and
SDMA with subclinical atherosclerosis [45, 46].
The well-defined cohort of patients with CAP of dif-
ferent severities is one of the main strengths of this
study. It is representative of patients usually treated in
hospital EDs. The long follow up over a period of 6 years,
the high rate of all-cause mortality, and the highly pre-
cise laboratory measurement methods are also worth
mentioning. A limitation of our study was that it was
Table 2 Association of initial biomarker levels with all-cause mortality at different time points
All-cause mortality time point
Entire Cohort (N = 268) 30 day 1 year 6 years
Cox regression models HR (95% CI); p value
Arginine
Univariate 1.04 (0.17 to 6.31); p = 0.968 2.19 (0.71 to 6.79); p = 0.175 1.10 (0.56 to 2.15), p = 0.791
Multivariatea 1.08 (0.14 to 8.45); p = 0.942 2.53 (0.74 to 8.74); p = 0.141 1.12 (0.52 to 2.41); p = 0.764
AUC 0.52 (0.33 to 0.71) 0.56 (0.46 to 0.66) 0.50 (0.43 to 0.57)
ADMA
Univariate 10.47 (0.72 to 152.55); p = 0.086 7.22 (1.81 to 28.77); p = 0.005 4.44 (1.84 to 10.74); p = 0.001
Multivariatea 5.79 (0.29 to 116.72); p = 0.252 3.33 (0.72 to 15.39); p = 0.124 1.91 (0.73 to 5.00); p = 0.188
AUC 0.67 (0.52 to 0.82) 0.67 (0.58 to 0.75) 0.65 (0.58 to 0.72)
SDMA
Univariate 15.79 (2.23 to 112.02); p = 0.006 5.62 (1.92 to 16.46); p = 0.002 2.81 (1.45 to 5.48); p = 0.002
Multivariatea 2.78 (0.17 to 44.74); p = 0.471 1.22 (0.39 to 3.86); p = 0.736 0.82 (0.44 to 1.52); p = 0.523
AUC 0.71 (0.56 to 0.87) 0.70 (0.61 to 0.8) 0.64 (0.57 to 0.71)
Arginine/ADMA Ratio
Univariate 0.36 (0.04 to 3.78); p = 0.398 0.44 (0.13 to 1.54); p = 0.198 0.33 (0.15 to 0.74); p = 0.007
Multivariatea 0.93 (0.12 to 7.31); p = 0.944 1.25 (0.33 to 4.68); p = 0.741 0.84 (0.36 to 1.93); p = 0.675
AUC 0.44 (0.25 to 0.63) 0.43 (0.32 to 0.53) 0.39 (0.32 to 0.46)
Data for univariate and multivariate Cox regression models are given as hazard ratio (95% CI); p value
Data regarding discrimination (prognostic accuracy) are given as area under the receiver operating characteristic curve (95% CI)
P values in bold type are statistically significant at p < 0.05
Abbreviations: ADMA Asymmetric Dimethylarginine, AUC area under the receiver operating characteristics curve, CI confidence interval, HR hazard ratio, SDMA
Symmetric Dimethylarginine
aMultivariate model: Admission concentration of logarithmic biomarkers adjusted for comorbidities (coronary artery disease, congestive heart failure, cerebrovascular
disease, peripheral artery occlusive disease, diabetes mellitus, chronic renal failure, neoplastic disease, and chronic obstructive pulmonary disease) and age
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carried out in hospitals in Switzerland and the results
may not be generalizable to other countries. In addition,
autopsies were not performed to validate the cause of
death, because of which this study only focused on all-
cause mortality. Third, this was only a hypothesis-
generating observational study. Fourth, the qSOFA score
was not measured at ED admission, as a result of which
we had to calculate the score on the basis of the infor-
mation we had. We took data on confusion from the PSI
score and counted it as an altered state of mind. Also
not all of our patients had information about the respira-
tory rate and the others had only an estimated rate. We
therefore have to assume that we undervalued the gen-
eral level of the qSOFA score. We also did not have data
on the severity of comorbidities (e.g., we only knew that
patients had a chronic kidney disease and not the stage
of the kidney disease). We also did not measure NO
levels and so cannot be sure that our conclusions are
complete. Finally, we did not have a complete marker
set available for all patients due to low blood specimen
volume. Nevertheless, our hypothesis-generating study
provides valuable information that will facilitate the de-
sign and conduct of additional studies in this area.
Conclusion
Deducing from our findings, we may assume that nei-
ther SDMA nor ADMA nor L-arginine are independ-
ently associated with all-cause mortality in CAP
patients, although strong unadjusted associations of
SDMA—more than ADMA—with mortality and comor-
bidities are seen in these patients. It remains unclear if
higher ADMA and SDMA levels cause higher mortality
or if higher mortality causes high levels of ADMA and
SDMA, and the precise role NO plays in this scheme of
events.
Given our findings, future studies should focus on
the causal connection between ADMA and SDMA
levels and mortality and on investigating the clinical
benefit of antagonising ADMA and SDMA (for ex-
ample, with L-arginine).
Abbreviations
ADMA: Asymmetric dimethylarginine; AUC: Area under the receiver
operating characteristic curve; BMI: Body mass index; CAD: Coronary artery
disease; CAP: Community-acquired pneumonia; CHF: Congestive heart
failure; CI: Confidence interval; CRF: Chronic renal failure; CRP: C-reactive
protein; DDAH: Dimethylarginine dimethylaminohydrolase; DM: Diabetes
mellitus; ED: Emergency department; HAP: Hospital-acquired pneumonia;
HR: Hazard ratio; IQR: Interquartile range; LC-MS/MS: Liquid chromatography
tandem-mass spectrometry; NO: Nitric oxide; NOS: Nitric oxide synthase;
PCT: Procalcitonin; PRMT: Protein arginine methyl transferase; PSI: Pneumonia
severity index; qSOFA: Quick Sepsis related Organ Failure Assessment: altered
mental status, fast respiratory rate (≥22 breaths per min), low blood pressure
(systolic blood pressure ≤100 mmHg); SDMA: Symmetric dimethylarginine
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